124 related articles for article (PubMed ID: 2832202)
1. Changes in pulmonary surfactant composition following MACC chemotherapy for lung carcinoma.
Rossi GA; Balbi B; Benatti U; Morelli A; Sacco O; Vassallo F; Ravazzoni C
Eur J Respir Dis; 1987 Nov; 71(5):400-9. PubMed ID: 2832202
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of the effects on the composition of alveolar surfactant of 2 chemotherapeutic protocols for carcinoma of the lung: peptichemio and MACC].
Balbi B; Benatti U; Morelli A; Sacco O; Vassallo F; Rossi GA; Ravazzoni C
Ann Ital Med Int; 1987; 2(1):22-30. PubMed ID: 3275275
[No Abstract] [Full Text] [Related]
3. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
[TBL] [Abstract][Full Text] [Related]
4. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
Robinson E; Haim N; Segal R; Veseley Z; Mekori T
Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
[TBL] [Abstract][Full Text] [Related]
5. MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer.
Buccheri G; Ferrigno D; Curcio A; Vola F; Mattalia E
Chemioterapia; 1986 Feb; 5(1):53-7. PubMed ID: 3955784
[TBL] [Abstract][Full Text] [Related]
6. [Polychemotherapy using methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) in patients with advanced adenocarcinoma and large cell carcinoma of the lung].
Karnicka-Młodkowska H; Jassem J; Mierzewski P; Słupek A; Mierzwa W; Decker E; Prokop A; Krawczyk K; Kowal E; Firlik M
Pneumonol Pol; 1986 Dec; 54(12):546-51. PubMed ID: 3035511
[No Abstract] [Full Text] [Related]
7. Tumor necrosis factor-alpha alters phospholipid content in the bronchoalveolar lavage-accessible space of isolated perfused rat lungs.
Hertzog JH; Godinez MH; Godinez RI
Crit Care Med; 1994 Dec; 22(12):1969-75. PubMed ID: 7988135
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
Buccheri G; Ferrigno D; Rosso A
Cancer; 1993 Sep; 72(5):1564-72. PubMed ID: 8394198
[TBL] [Abstract][Full Text] [Related]
9. [MACC plus thymostimulin (TP-1 Serono) therapy of small cell bronchogenic carcinoma. Clinico-immunologic evaluation of the results of a randomized trial].
Salvati F; Pallotta G; Antilli A; Nunziati F; De Marinis F; Lucchesi M
G Ital Chemioter; 1984; 31(1-2):185-9. PubMed ID: 6088341
[No Abstract] [Full Text] [Related]
10. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG).
Buccheri G; Ferrigno D
Eur J Cancer; 1994; 30A(10):1424-31. PubMed ID: 7833096
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary surfactant in patients with Pneumocystis pneumonia and acquired immunodeficiency syndrome.
Schmidt R; Markart P; Ruppert C; Temmesfeld B; Nass R; Lohmeyer J; Seeger W; Günther A
Crit Care Med; 2006 Sep; 34(9):2370-6. PubMed ID: 16849999
[TBL] [Abstract][Full Text] [Related]
12. [Surfactant lipids of bovine lungs].
Ledwozyw A; Tusińska E; Tusiński M
Pol Arch Weter; 1991; 31(3-4):93-104. PubMed ID: 1842618
[TBL] [Abstract][Full Text] [Related]
13. Lessons from a time capsule: evolution, not revolution, in therapy for advanced non-small-cell lung cancer.
Green MR
J Clin Oncol; 2008 Jul; 26(19):3112-3. PubMed ID: 18591551
[No Abstract] [Full Text] [Related]
14. Random prospective study cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non small cell lung cancer.
Einhorn LH; Williams SD; Stevens EE; Bond WH; Chenoweth L
Cancer Treat Rep; 1982 Dec; 66(12):2005-11. PubMed ID: 6291763
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of platinum-based regimens in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group.
Buccheri G; Ferrigno D
Lung Cancer; 1997 Aug; 18(1):57-70. PubMed ID: 9268948
[TBL] [Abstract][Full Text] [Related]
16. [Value of polychemotherapy for bronchogenic carcinoma other than undifferentiated small cell carcinoma].
Laberge F; Desmeules M; Bergeron D; La Forge J; Cormier Y
Union Med Can; 1984 Mar; 113(3):222-4. PubMed ID: 6730096
[No Abstract] [Full Text] [Related]
17. [Phospholipids and fatty acids in pulmonary surfactant of patients with lung cancer].
Jabłonka S; Ledwozyw A; Kadziołka W; Modrzewski Z
Pneumonol Pol; 1989 May; 57(5):270-6. PubMed ID: 2633144
[TBL] [Abstract][Full Text] [Related]
18. [The surfactant system and ultrastructure of the lungs after surgical correction of cardiac defects during extracorporeal circulation].
Perezhogin EV; Zaĭtseva KK; Skorik VI; Grigor'eva IuA; Aleshkin NG
Arkh Patol; 1989; 51(1):30-7. PubMed ID: 2719560
[TBL] [Abstract][Full Text] [Related]
19. Comparison of combination chemotherapy programs in advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study.
Krook JE; Fleming TR; Eagan RT; Cullinan S; Pfeifle D; Elliott T; Etzell P
Cancer Treat Rep; 1984 Mar; 68(3):493-8. PubMed ID: 6322987
[TBL] [Abstract][Full Text] [Related]
20. [Dry extract of Scutellaria baicalensis as a hemostimulant in antineoplastic chemotherapy in patents with lung cancer].
Gol'dberg VE; Ryzhakov VM; Matiash MG; Stepovaia EA; Boldyshev DA; Litvinenko VI; Dygaĭ AM
Eksp Klin Farmakol; 1997; 60(6):28-30. PubMed ID: 9460593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
